zocilurtatug pelitecan

News

Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.

News

BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.